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Mutations in the extracellular domain of the 55-kD tumor-necrosis factor (TNF) receptor (TNFRSF1A), a key
regulator of inflammation, define a periodic-fever syndrome, TRAPS (TNF receptor–associated periodic syndrome
[MIM 142680]), which is characterized by attacks of fever, sterile peritonitis, arthralgia, myalgia, skin rash, and/
or conjunctivitis; some patients also develop systemic amyloidosis. Elsewhere we have described six disease-asso-
ciated TNFRSF1A mutations, five of which disrupt extracellular cysteines involved in disulfide bonds; four other
mutations have subsequently been reported. Among 150 additional patients with unexplained periodic fevers, we
have identified four novel TNFRSF1A mutations (H22Y, C33G, S86P, and c.193514 GrA), one mutation (C30S)
described by another group, and two substitutions (P46L and R92Q) present in ∼1% of control chromosomes.
The increased frequency of P46L and R92Q among patients with periodic fever, as well as functional studies of
TNFRSF1A, argue that these are low-penetrance mutations rather than benign polymorphisms. The c.193514
GrA mutation creates a splice-acceptor site upstream of exon 3, resulting in a transcript encoding four additional
extracellular amino acids. T50M and c.193514 GrA occur at CpG hotspots, and haplotype analysis is consistent
with recurrent mutations at these sites. In contrast, although R92Q also arises at a CpG motif, we identified a
common founder chromosome in unrelated individuals with this substitution.Genotype-phenotype studies identified,
as carriers of cysteine mutations, 13 of 14 patients with TRAPS and amyloidosis and indicated a lower penetrance
of TRAPS symptoms in individuals with noncysteine mutations. In two families with dominantly inherited disease
and in 90 sporadic cases that presented with a compatible clinical history, we have not identified any TNFRSF1A
mutation, despite comprehensive genomic sequencing of all of the exons, therefore suggesting further genetic het-
erogeneity of the periodic-fever syndromes.
Introduction
Until recently, the dominantly inherited periodic-fever
syndromes represented a poorly understood group of
inflammatory diseases. Clinically, these disorders are
characterized by recurrent prolonged (11 wk) attacks of
fever associated with abdominal pain, myalgia, migra-
tory erythematous skin rash, conjuctivitis, and/or per-
iorbital edema (McDermott et al. 1997). In contrast to
patients with familial Mediterranean fever (FMF [MIM
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249100]), which is recessively inherited, patients with
dominantly inherited periodic fever usually have a poor
response to colchicine but a favorable response to cor-
ticosteroids. Dominantly inherited periodic fevers have
been described mostly in families of northern-European
descent (Williamson et al. 1982; Gertz et al. 1987;
McDermott et al. 1997; Zaks and Kastner 1997).
In 1998, linkage studies identified, in the same region
of chromosome 12p13, a candidate interval for two
clinical variants—benign autosomal dominant familial
periodic fever (FPF) (Mulley et al. 1998) and familial
Hibernian fever (FHF [MIM 142680]) (McDermott et
al. 1998). One of the several candidate genes in this
interval is TNFRSF1A, the gene encoding the 55-kD
receptor for tumor-necrosis factor (TNF) a (TNF-a).
Subsequently, in 1999 we identified six mutations in the
TNFRSF1A sequence encoding the extracellular domain
of the p55 receptor in seven affected families, including
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those previously denoted as having FPF and FHF
(McDermott et al. 1999). This was the first report of
TNFRSF1A mutations in human disease.
In our initial report, all of the mutations were single-
nucleotide missense substitutions, with five of the six
mutations disrupting highly conserved cysteine residues
involved in extracellular disulfide bonds. Although five
of the first seven families were of either Irish or Scottish
descent, one was Finnish and another was French Ca-
nadian. In light of the more diverse ethnic distribution,
we have proposed the term “TNF receptor–associated
periodic syndrome” (TRAPS) for those patients with
TNFRSF1A mutations.
In vitro studies of leukocytes from patients bearing
the C52F mutation indicated an impairment in the nor-
mal activation-induced cleavage of cell-surface p55 re-
ceptors. Receptor clearance is thought to have a nega-
tive homeostatic effect, both by preventing repeated
stimulation through membrane p55 and by creating a
pool of antagonistic soluble receptors, and thus a cleav-
age defect could at least partially account for the hy-
perinflammatory phenotype in TRAPS.
Four additional TRAPS mutations in the extracellu-
lar domain of TNFRSF1A have subsequently been re-
ported by other groups: C30S (Dode´ et al. 2000), R92P
(Aganna et al. 2001), C55S (Jadoul et al. 2001), and
C70Y (Simon et al. 2001). Families were of French,
Dutch, Belgian, and Dutch-Indonesian descent, respec-
tively. Individuals affected with each mutation mani-
fested typical TRAPS inflammatory attacks, and amy-
loidosis was documented in patients with either the
C70Y mutation or the C55S mutation.
Here we report a new group of patients with TRAPS,
including both familial and sporadic cases. We identified
four mutations, two of which were cysteine substitutions,
that were not present among a panel of ethnically
matched control chromosomes. Two other substitutions,
neither of which involved cysteines, were found in ∼1%
of control chromosomes. On the basis of their clinical
presentation, their higher frequency among periodic fever
patients, and functional studies of TNFRSF1A in vitro
and in vivo, these latter two substitutions are likely to
be low-penetrance mutations rather than polymor-
phisms. We have also investigated the carrier haplotypes
associated with mutations observed in unrelated patients,
the penetrance of the 16 known TRAPS mutations, and
possible genotype-phenotype relationships. Our data
strongly suggest that cysteine substitutions lead to a
higher risk of amyloidosis—and, probably, to a higher
penetrance—than do the noncysteine mutations. Finally,
we report evidence for further genetic heterogeneity of
periodic-fever syndromes, with one clinically consistent
family not having linkage to chromosome 12p13 and
with 90 sporadic cases without demonstrable mutations
in the coding region of TNFRSF1A.
Subjects, Material, and Methods
Patients and DNA Specimens
The present study included patients referred to the
National Institutes of Health for clinical and/or molec-
ular diagnosis of unexplained periodic fevers. The study
was approved by the human-experimentation committee
at the National Institutes of Health, and consent was
obtained from all participants. Genomic DNA was ex-
tracted from whole blood by a commercially available
kit (Puregene; Gentra Systems).
TNFRSF1A Mutation Detection
Genomic DNAs from 150 patients (137 unrelated in-
dividuals) with symptoms compatible with TRAPS were
sequenced for exons 2–5 of TNFRSF1A, encoding the
extracellular domain, as described elsewhere (McDermott
et al. 1999). Samples of genomic DNA from 90 patients
were analyzed by the combination of denaturing high-
performance liquid chromatography (DHPLC) and se-
quence analysis, for all 10 exons of TNFRSF1A. Patients
from two families initially negative for a mutation in the
extracellular domain of the gene were also sequenced
through the complete coding region and promoter (450
bp). The forward and reverse oligonucleotide primers
used to amplify regulatory sequences of the TNFRSF1A
gene were 5′-TCACTGCTGTGATCCATCTGGG-3′ and
5′-TTCTCACCAGTGGCAGCAGCAG-3′. Other exons
were sequenced as described elsewhere (McDermott et al.
1999), except that exons 8 and 9 were analyzed sepa-
rately, with the following primers: exon 8, forward prim-
er 5′-TCGAGCTGCATCAGTAGCTCT-3′ and reverse
primer 5′-TTCTACGTGGGGGTTGGGAC-3′; exon 9,
forward primer 5′-TAAGTCCCAACCCCCACGTAG-3′
and reverse primer 5′-CAGCCTCCTCGTCTCCAG-3′.
Mutation detection was performed by fluorescent se-
quencing with dye-primer chemistry (Amersham), on an
ABI 377 automated sequencer, and by DHPLC (Trans-
genomics). PCR was performed with AmpliTaqGold (PE
Biosystems) in 50-ml reactions with 10–50 ng of genomic
DNA and with the same primers, described above, that
were used for exon sequencing. DHPLC analysis of am-
plicons was performed at temperatures modified for each
of the exons, according to WAVE-MAKER 4.0 software
(Transgenomics). Amplicons showing a DHPLC elution
shift were confirmed in a repeat sequencing analysis. The
sequencing data were analyzed by SEQUENCHER 3.0
(Gene Codes).
Microsatellite and Single-Nucleotide Polymorphism
(SNP) Analysis
Genotyping in the chromosomal region of the
TNFRSF1A locus was performed with the following
Aksentijevich et al.: TNFRSF1A Mutations in TRAPS 303
markers: D12S99, D12S356, TNFRP55, CD4,
D12S1695, D12S77, and D12S364, as described else-
where (McDermott et al. 1998; Mulley et al. 1998; Es-
kadele et al. 2000). The two intragenic SNPs utilized in
the present study were recently reported (Bazzoni et al.
2000) and have been submitted to HGSBASE, with ac-
cession numbers SNP000005194 and SNP000005195.
Allele frequencies of G (.47) and of A (.53), for
SNP000005194 (exon 1 SNP), and of C (.32) and of
T (.68), for SNP000005195 (intron 5 SNP), were de-
termined in 71 healthy controls. TNFRSF1A intragen-
ic SNPs of our patients were determined by DNA
sequencing.
Genotyping for the Muckle-Wells syndrome (MWS
[MIM 191900])/familial cold urticaria (FCU [MIM
120100]) locus on distal chromosome 1q44 was per-
formed with the D1S2682 and D1S423 microsatellites,
which define the boundaries of the MWS/FCU critical
interval (Cuisset et al. 1999; Hoffman et al. 2000;
McDermott et al. 2000). Since the marker D1S423 was
not informative, we also used two other microsatellites
close to the centromeric boundary of the candidate in-
terval,D1S1609 andD1S547.Microsatellite haplotypes
were constructed so as to minimize the number of in-
trafamilial recombinations.
RNA Extraction
Total RNA was extracted from leukocytes by use of
Trizol Reagent (GIBCO-BRL), as described elsewhere
(Centola et al. 2000). First-strand cDNA synthesis was
performed with the GIBCO Superscript Preamplification
System, according to the manufacturer’s recommenda-
tions. The cDNA template was amplified by PCR with
the following primers: forward primer 5′-ATTGGACT-
GGTCCCTCACCTAGGG-3′ and reverse primer 5′-TC-
TCACACTCCCTGCAGTAC-3′.
Construction of a Minigene to Analyze Aberrant
Splicing
DNA fragments comprising exon 2, intron 3, and
exon 3 were obtained, by PCR amplification, from the
proband and control DNA samples, by use of the fol-
lowing oligonucleotides: forward primer 5′-CGAGAAT-
TCATGCGTGCTCCTGGAGCTGTTGGTG-3′ and re-
verse primer 5′-TCGCTCGAGTCACCTTTCGGCAT-
TTGGAGCAGCTG-3′. The forward primer contained
an EcoRI restriction site and four nucleotides (ATGC),
to create a methionine codon in-frame with the open
reading frame of exon 2; the reverse primer contained
an XhoI site followed by a stop codon. PCR amplifi-
cation was performed with AmpliTaq Gold (PE Applied
Biosystems), and cycling conditions were 94C for 30 s,
60C for 30 s, and 72C for 30 s, for 30 cycles, followed
by extension at 72C for 7 min. The amplicons were
ligated into pCR2.1 vector by use of the TOPO TA clon-
ing kit (Invitrogen), and the resulting colonies were an-
alyzed, by restriction digestion and dye-primer sequenc-
ing, for expected mutation-containing inserts. Verified
inserts were cloned into pcDNA3 expression vector (In-
vitrogen) by ligation of the XhoI/EcoRI insert fragments
from TA clones with XhoI/EcoRI-digested vector. Ex-
pression plasmids were transfected into Cos-7 cells by
use of Lipofectamine reagent (Gibco/BRL), as described
by the manufacturer. After 24 h of expression, RNAwas
extracted from transfected cells by use of Trizol reagent
(Gibco/BRL), and bulk cDNA was prepared by the
GIBCO Superscript Preamplification System, according
to the manufacturer’s recommendations.
Cell Activation and Flow-Cytometric Analysis
TNFRSF1A shedding assays were performed as de-
scribed elsewhere (McDermott et al. 1999). In brief,
blood cells were washed and incubated at 37C for 10
min in Hanks’ balanced salt solution containing 1% fetal
calf serum (FCS), with or without 4-b-phorbol 12-myr-
istate 13-acetate (PMA; Sigma). Cells were washed with
HBSS/1% FCS at 4C, and erythrocytes were lysed by
use of ammonium chloride potassium lysing buffer
(BioWhittaker). Cells were incubated with phycoery-
thrin (PE)-conjugated anti-TNFRSF1A monoclonal an-
tibodies (Caltag) and isotype controls (Becton Dickin-
son), for 30 min at 4C, and were washed three times
with phosphate-buffered saline containing 0.5% bovine
serum albumin. Expression of membrane TNFRSF1A on
monocytes was analyzed by flow cytometry, by a FACS
Calibur flow cytometer (Becton Dickinson). Soluble lev-
els of TNFRSF1A were detected by solid-phase enzyme-
linked immunosorbent assay, as described elsewhere
(McDermott et al. 1999).
Statistical Analysis
Statistical analyses were performed by the SAS 6.12
and Epi Info 6 statistical software packages (Centers for
Disease Control and Prevention [CDC]). Comparison of
cysteine mutations, in patients versus a control group of
healthy individuals and in patients with amyloidosis ver-
sus patients without amyloidosis, were performed by x2
statistics. Results were reported as odds ratios with 95%
confidence intervals. All P values were Yates corrected.
Results
TNFRSF1A Mutational Survey
At the National Institutes of Health Clinical Center, a
referral center for periodic-fever syndromes, we collected
DNA samples from 1800 patients suffering from periodic
fever and accompanying symptoms. The 150 patients
who underwent screening for mutations in TNFRSF1A
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Figure 1 TRAPS pedigrees with novel TNFRSF1A mutations. Affected individuals are indicated by blackened symbols; individuals who
are mutation positive but asymptomatic are represented by gray-shaded symbols. For the H22Y, R92Q, and c.19314 GrA mutations, only
representative families are shown.
were selected on the basis of a clinical history suggestive
of TRAPS (i.e., attacks lasting 11 wk, characteristic skin
rash, and/or nonresponsiveness to colchicine). The pa-
tients were screened for mutations in exons 2–5 of
TNFRSF1A, where all of the initially reported mutations
clustered (McDermott et al. 1999). We used automated
sequencing of PCR-amplified genomic DNAs, since, in
our initial report, all but one of themutations was private.
Ninety patients underwent further comprehensive anal-
ysis of the entire TNFRSF1A coding region (i.e., 10 ex-
ons). This new cohort of patients with TRAPS with de-
monstrable TNFRSF1A mutations included several
multiplex families and 10 sporadic cases of various ethnic
backgrounds. Representative pedigrees are shown in fig-
ure 1.
Among these patients, we identified seven new
TNFRSF1A mutations, one of which was recently re-
ported by another group (Dode´ et al. 2000). The mu-
tations are listed in table 1, and corresponding DNA-
sequence electropherograms are shown in figure 2.
Amino acid positions are defined relative to the signal
peptide–cleavage site. H22Y is a novel mutation detected
in the father and three affected children in a family of
Scottish/German background and in one case, of mixed
northern-European background, that initially appeared
to be sporadic, with lifelong unexplained periodic fevers
leading to 170 hospitalizations and 13 exploratory sur-
geries. Subsequently, we found that the latter patient’s
father, who is also of mixed northern-European back-
ground, also suffered from mild symptoms of TRAPS
and bore the H22Y mutation. This substitution was not
observed either in the only available healthy member
(i.e., the mother) of each H22Y-positive family or in any
of 1100 northern-European control chromosomes
screened by genomic sequencing.
C30S and C33G mutations were found at the same
highly conserved cysteine residues where we previously
had reported the C30R and C33Y mutations, and nei-
ther C30S nor C33Gwas found in any of 1100 northern-
European control chromosomes. The C30S mutation
was observed in an Irish American family with three
affected members, and has also recently been described
in a French family (Dode´ et al. 2000). The C33G mu-
tation was found in a father and daughter originally
from Puerto Rico, with histories of recurrent fever, ab-
dominal pain, and arthralgia since birth. They had been
treated with corticosteroids for many years. The father
had developed progressive hepatic amyloidosis, even-
tually necessitating liver transplantation. The mother
and their other three children were healthy and negative
for this mutation.
S86P is a new private mutation found in a three-gen-
eration family, of Scottish/Irish descent, with four af-
fected members (fig. 1) who experienced episodes of se-
vere abdominal pain, high fever, and arthralgia lasting
6–8 wk. This substitution was observed in none of 100
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Figure 2 DNA sequence electropherograms for the seven
TNFRSF1A mutations identified in the present study. For each se-
quence, the upper tracing is from a patient, and the lower tracing is
from a normal control.
Table 1
Summary of New TRAPS Mutations
MUTATION
(NUCLEOTIDE CHANGE) LOCATION
NO. OF
ETHNICITYPatients Families
H22Y (151 CrT) Exon 2 6 2 Scottish/German, mixed northern European
C30S (176 GrC) Exon 2 3 1 Irish
C33G (184 TrG) Exon 2 2 1 Puerto Rican
P46L (254 CrT) Exon 2 1 1 African American/northern European
S86P (343 TrC) Exon 4 4 1 Scottish/Irish
R92Q362 GrA Exon 4 9 9 Mexican (1), Italian (2), Irish (1), English (1), Portuguese (1), Ashkenazi (1),
mixed northern European (2)
Splice (c.19314 GrA) Intron 3 5 2 Scottish/Arab
northern-European control chromosomes. One of the
affected sibs in the third generation is symptomatic but
declined genetic testing.
Screening of intronic sequences flanking the exons
identified one splicing mutation. In a family of Scottish
descent and in a family of Arab descent (fig. 1; Scottish
family is not shown), we observed a GrA change in
intron 3 at position 14 relative to codon 193 (fig. 2).
This substitution was not detected in any of 100 control
chromosomes and potentially could create a new con-
sensus splice-acceptor sequence (i.e., AG) in the presence
of a preceding polypyrimidine tract (fig. 3A). We ob-
tained mRNA from one of the patients carrying this
substitution, performed reverse transcriptase–PCR, and
detected a band slightly larger than the normal-size tran-
script. Sequencing of the cloned larger band revealed a
transcript encoding an additional four amino acids, as
would be expected with activation of this new splice-
acceptor site in intron 3.
We also analyzed the effect of this substitution on pre-
mRNA splicing, by examining Cos-7 cells transfected
with a minigene construct harboring either the mutant
A nucleotide or the wild-type G. Cytoplasmic RNA iso-
lated from transfected Cos-7 cells showed that the mu-
tant construct produced aberrantly spliced transcript
with an extra four amino acids inserted between exons
2 and 3 (fig. 3B). The wild-type construct resulted in
normal splicing of the TNFRSF1A transcript. This sub-
stitution cosegregated with affection status in both fam-
ilies but with reduced penetrance in two members of the
Arab family and in one member of the Scottish family.
Low-Penetrance TNFRSF1A Mutations
Finally, two additional missense transitions, P46L and
R92Q, were identified in patients with periodic fever and
at low frequencies in the general population. P46L was
detected in one sporadic patient of mixed ancestry who
suffered from periodic fevers that sometimes lasted 11mo
and that were associated with severe abdominal pain,
vomiting, and leg pain. We found that the patient inher-
ited this substitution from his father, who is of mixed
African American and northern-European ancestry. P46L
was detected in 1 of 170 northern-European control chro-
mosomes and in 3 of 156 African American control chro-
mosomes, at a combined gene frequency of 1.23%.R92Q
was the most common TNFRSF1A sequence change iden-
tified in our panel, occurring in 9 of 137 unrelated pa-
306 Am. J. Hum. Genet. 69:301–314, 2001
Figure 3 A, Diagram of normal and aberrantly spliced TNFRSF1A transcript. The conventional splice-donor site, splice-acceptor site,
and mutated nucleotide in intron 3 are in boldface. The c.19314 GrA mutation creates a new splice-acceptor site, as shown. Single-letter
designations for amino acids are shown immediately above the first nucleotide in each codon. Four additional amino acids that are present in
the alternatively spliced transcript are encoded by the nucleotides that are underlined. B, DNA-sequence electropherograms showing in vitro
splicing of c.19314 GrA transcripts (top) and normal transcripts (bottom) in Cos-7 cells.
tients. All were sporadic cases, representing a range of
ethnicities. Since, in five cases, this substitution was de-
tected in asymptomatic parents, we investigated the fre-
quency of R92Q in the Irish and North American control
populations. R92Q was detected in 2 of 132 Irish control
chromosomes and in 6 of 634 North American (mostly
northern-European) control chromosomes, at a combined
gene frequency of 1.04% in both populations, versus 9
(3.3%) of 274 independent chromosomes in the panel
with a clinical picture suggestive of TRAPS ( ).Pp .02
To explore further the significance of P46L and R92Q,
we examined cell-surface TNFRSF1A in peripheral blood
monocytes before and after in vitro stimulation with
PMA. We have previously demonstrated that leukocytes
from patients with the C52F mutation show both in-
creased baseline levels of membrane TNFRSF1A and, af-
ter stimulation with PMA, a potent inducer of the me-
talloproteases mediating ectodomain cleavage, reduced
receptor cleavage (shedding). Figure 4 shows TNFRSF1A
expression on monocytes from patients bearing the C52F,
T50M, P46L, or R92Q substitutions and from a con-
trol sample. As previously reported, unstimulated C52F
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Figure 4 Defective clearance of TNFRSF1A in patients with
TRAPS. Monocytes were analyzed for TNFRSF1A expression (thicker
line in each panel), before (left-hand panels) or after (right-handpanels)
PMA activation (100 ng/ml) for 10 min. Single-cell suspensions (106
cells) were incubated with either anti–TNFRSF1A-PE or isotype-
matched IgG-PE as control (thinner line in each panel), were washed,
and were analyzed by flow cytometry. Fluorescence histograms are
shown for controls and for patients with the C52F, T50M, P46L, and
R92Q TRAPS mutations.
Table 2
TNFRSF1A Mutations and
Development of Amyloidosis
Mutation
Frequency
of Amyloidosis
H22Y 0/6
C30R 2/2
C30S 0/5
C33G 1/2
C33Y 2/17
P46L 0/1
T50M 1/18
C52F 3/5
C55S 3/3
C70Y 1/8
S86P 0/4
C88R 0/8
C88Y 1/4
R92P 0/3
R92Q 0/9
Splice 0/5
Total 14/100a
a Of the 14 cases of amyloidosis,
13 (93%) had cysteine mutations.
monocytes, relative to controls, had more membrane
TNFRSF1A and showedminimal receptor clearance, after
PMA stimulation. Comparable results, both before and
after PMA stimulation, were observed with cells bearing
T50M. Consistent with the view that P46L has functional
consequences, monocytes from patients bearing this sub-
stitution did not completely clear TNFRSF1A after PMA
stimulation, although there was more shedding than was
seen with either T50M or C52F. Variable degrees of im-
pairment of PMA-induced TNFRSF1A shedding were
also observed in monocytes from patients with the H22Y,
C30S, or C33G mutations (data not shown).
In contrast, monocytes from patients bearing the
R92Q substitution showed TNFRSF1A membrane
staining and receptor shedding comparable to those in
controls (fig. 4). Similar results were also observed for
monocytes from patients with the c.19314 GrA mu-
tation (data not shown). Nevertheless, when we exam-
ined serum samples from a patient with R92Q that were
taken during and between febrile episodes, we found that
soluble p55 levels failed to increase with the attack
(3,358 pg/ml baseline, 1,997 pg/ml during attack, nor-
mal range 749–1,966 pg/ml). Similar findings have re-
cently been reported for the C30S mutation (Dode´ et al.
2000). The failure of patients’ soluble TNFRSF1A levels
to increase with inflammatory episodes suggests an in
vivo functional abnormality that, in the case of R92Q,
is not detected by the in vitro shedding assay.
Genotype-Phenotype Studies
When the present study is included, 100 symptomatic
patients positive for a total of 16 mutations in
TNFRSF1A have been reported in the literature
(McDermott et al. 1999; Dode´ et al. 2000; Aganna et
al. 2001; Jadoul et al. 2001; Simon et al. 2001). Because
systemic amyloidosis is the most serious manifestation
of TRAPS, sometimes leading to hepatic and/or renal
failure and death, we first investigated the possible as-
sociation of amyloidosis with specific mutations (table
2). Among the 100 patients with TRAPS, this compli-
cation has been identified in 14. Despite the fact that
only 9 of 16 known mutations in TNFRSF1A involve
cysteine residues, 13 of 14 known cases of amyloidosis
occurred among patients with cysteine mutations
(C30R, C33G, C33Y, C52F, C55S, C70Y, or C88Y);
only 1 patient with amyloidosis had T50M. When un-
affected carriers of mutations were included, amyloi-
dosis was found in 13 of 59 persons with cysteine sub-
stitutions but in only 1 of 58 with noncysteinemutations
( , by Fisher’s exact test; odds ratio 16.11, 95%Pp .002
CI 2.06–341.95).
We also analyzed family data for the 16 known
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Table 3
Microsatellite and Intragenic SNP Haplotypes of TRAPS T50M Carrier Chromosomes and of R92Q Carrier Chromosomes
Subject (Ethnicity)
Marker
D12S99
Marker
D12S356
Exon 1
SNP
Marker
TNFRp55
Intron 5
SNP
Marker
CD4
Marker
D12S1695
Marker
D12S77
Haplotype
Designation
T50M
Patient 466 (Scottish) 299/303 215/219 A/G 144/150 C/T 86/86 147/155 191/183 1
Patient 469 (Scottish), child of 466 299/297 219/219 A/A 150/150 T/T 86/112 147/155 191/173 1
Patient 594 (unknown) 303/303 215/217 A/A 148/150 T/T 91/112 157/161 173/173 1
Father of 594, unaffected ND ND A/A 150/150 T/T 91/106 ND ND
Patient 32 (Irish) 293/297 219/223 A/G 144/152 C/T 86/86 157/159 163/163 2
Patient 510 (Irish), child of 32 293/297 219/223 A/A 150/152 T/T 86/91 155/159 ND 2
Patient 511 (Irish), child of 32 293/293 297/223 A/A 150/152 T/T 86/91 155/159 ND 2
Patient 802 (Irish) ND 223/225 A/G 144/150 C/T 106/106 ND ND 3
Patient 804 (Irish) ND ?/225 A/G 144/152 C/T 101/106 ND ND 3
Patient 805 (Irish) ND 223/225 A/G 144/150 C/C 91/106 ND ND 3
Patient 806 (French Canadian) ND 219/223 G/G 144/144 C/C 86/91 ND ND 3
Patient 807 (French Canadian), child of 806 ND 219/223 G/G 144/144 C/C 86/91 ND ND 3
R92Q
Patient 498 (mixed northern European) 295/297 211/211 G/G 140/144 C/C 91/91 147/155 177/177
Mother of 498 295/295 211/219 A/G 140/152 ND 91/112 147/159 ND
Patient 522 (Irish) 293/297 219/223 A/G 140/150 C/T 86/91 147/157 167/179
Patient 560 (Mexican) 297/303 217/221 A/G 140/150 C/T 86/86 147/155 177/181
Mother of 560 297/301 213/217 G/G 140/144 C/C 86/112 155/159 177/177
Patient 618 (English) 293/301 211/213 A/G 140/150 C/T 91/112 159/161 163/181
Patient 644 (Italian) 297/301 217/223 A/G 140/150 C/T 86/86 147/151 177/185
Patient 657 (Portuguese) 297/? 205/221 A/G 140/150 C/T 91/121 151/155 179/?
Father of 657 293/297 205/217 G/G 140/144 C/C 91/121 155/155 179/?
Patient 670 (unknown) 301/? 205/211 G/G 140/150 C/C 91/112 141/155 181/183
Father of 670 301/303 205/219 A/G 140/144 C/C 86/91 147/155 181/?
Patient 758 (mixed northern European) ND 221/223 A/G 140/152 C/C 91/106 ND ND
Patient 791 (Jewish) ND 217/223 G/G 140/144 C/C 91/91 ND ND
Father of 791 (Jewish) ND 223/225 G/G 140/144 C/C 91/91 ND ND
NOTE.—The genetic markers are presented in the order in which they occur on chromosome 12. Alleles representing haplotypes segregating
with either T50M or R92Q within the family are in boldface italic; alleles representing a putative haplotype cosegregating with a mutation,
determined on the basis of allele similarities with other defined haplotypes, are underlined. NDp not determined; ?p results not interpretable.
TRAPS mutations, to compare the penetrance of cysteine
and noncysteine mutations. In our study and in data
published by other groups (Dode´ et al. 2000; Simon et
al. 2001), 5 of 59 individuals identified with cysteine
TNFRSF1A mutations had no reported symptoms, ver-
sus 12 of 58 individuals with noncysteine mutations
( ; Aganna et al. 2001; present study). Only 1 ofPp .11
18 individuals positive for the T50M mutation was
asymptomatic. Therefore, the total number of individ-
uals positive for TNFRSF1A mutations was 117, with
100 of them being symptomatic carriers of various mu-
tations and with 17 being asymptomatic carriers of var-
ious mutations.
Haplotype Analysis
We next asked whether unrelated carriers of the same
mutation share a common founder haplotype. Data rel-
evant to this issue were available for three mutations:
T50M, R92Q, and c.19314 GrA. T50M was initially
observed in eight affected members of an Irish family
with FHF (including patients 802, 804, and 805 in table
3) and in one available member (patient 806) of a French
Canadian family (McDermott et al. 1999). Additionally,
we found this mutation in 10 other patients: 3 members
(patients 32, 510, and 511) of an Irish American family,
2 patients (patients 466 and 469) from a Scottish Amer-
ican family, 1 additional member (patient 807) of the
French Canadian family, 1 patient (patient 594) from
the United States who is of unknown descent, and, re-
cently, 3 members of another Scottish American.
To test the hypothesis of common ancestry, we con-
structed haplotypes with both microsatellite and in-
tragenic SNP markers. TNFR1P55 is an intragenic mi-
crosatellite marker that resides within intron 2 of
TNFRSF1A (based on the genomic structure used by
Fuchs et al. 1992), and we tested additional SNPs in
exon 1 and in intron 5. D12S99 and D12S356 are
telomeric flanking markers, whereas CD4, D12S1695,
and D12S77 are centromeric flanking markers. The se-
quence of these markers and the published genetic dis-
tances between them are as follows: D12S99–.02–
D12S356–.02–TNFRSF1A–.01–CD4–.03–D12S1695–
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Figure 5 Pedigree of family affected with dominantly inherited periodic-fever syndrome. One affected member of the family was screened
for the TNFRSF1A mutation, throughout the coding and promoter regions; no mutation was identified. Linkage analysis was done to rule out
other mutations in TNFRSF1A. Genotypes for six DNA markers from chromosome 12p are shown. Affected sibs in the second generation
inherited opposite haplotypes across the interval.
.03–D12S77. Haplotypes were deduced from the rele-
vant pedigrees. Among five families with T50M (the re-
cently reported Scottish American family was not stud-
ied), we identified three intragenic haplotypes: A-150
bp-T, A-152 bp-T, and G-144 bp-C (table 3). In addition,
we did not find a common microsatellite founder hap-
lotype associated with the c.19314 GrA splicing mu-
tation, consistent with the fact that this mutation was
detected in two families of very distinct ethnicity (data
not shown).
However, haplotype analysis of patients with R92Q
showed a high level of linkage disequilibrium within
TNFRSF1A, where the 140-bp allele of the TNFR1P55
microsatellite marker cosegregated strongly with the
presence of the substitution at codon 92. Using this mi-
crosatellite and the two intragenic SNPs, we have iden-
tified an intragenic haplotype, defined as G-140 bp-C,
associated with the R92Q mutation on all of four in-
dependent carrier chromosomes in which phase could
be assigned (table 3). In all five remaining singleton
cases, in which phase could not be established, genotypes
consistent with this intragenic haplotype were observed.
In contrast, the frequency of this haplotype in the general
northern-European population could not be 16.5%, the
frequency of the 140-bp allele that we observed in 122
control chromosomes.
Genetic Heterogeneity
Among the families with a clinical history compatible
with TRAPS who were referred for periodic fever, two
multiplex families with dominant inheritance were
identified. We did not find any mutation in TNFRSF1A,
even after sequencing all of the exons, flanking intronic
regions, and promoter regulatory sequences. One of the
families was a three-generation pedigree with affected
members in each generation—and, therefore, was infor-
mative for linkage analysis. Even though the first two
markers were not informative in this family, from
TNFRP55 to D12S364 opposite haplotypes were in-
herited in the two affected siblings in the second gen-
eration (fig. 5), thus ruling out TNFRSF1A mutations
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Figure 6 Genomic structure of TNFRSF1A (adapted from Fuchs et al. 1992). All 16 known TRAPS-causing mutations are clustered in
exons 2–4, which encode the TNFRSF1A extracellular domain. The c.2189 TrC polymorphism is shown in intron 8 of TNFRSF1A.
Figure 7 Crystallographically determined structure of the
TNFRSF1A extracellular domains 1 and 2 (Banner et al. 1993). TRAPS
mutations are shown as circled amino acids. The three disulfide bonds
of CRD1 and CRD2 are depicted by thick black bars. Structurally
conserved regions of the CRDs are represented by thicker lines. The
b-turn positions are indicated by “b.” Loop domains are denoted as
“L1”–“L3.”
3′ to this microsatellite locus in the intron following exon
1. When these results are considered together with our
sequence analysis of exon 1 and the promoter region, it
is highly unlikely that TNFRSF1A is the susceptibility
locus. The hyperimmunoglobulinemia D with periodic
fever syndrome (HIDS [MIM 260920]) and FMF were
considered in the differential diagnosis, but the domi-
nant pattern of inheritance is not consistent with either
of these diagnoses. Nevertheless, the affected members
were screened for a panel of 19 known FMF mutations;
and they tested negative. Linkage analysis for the MWS/
FCU region on distal chromosome 1q44 also identified
recombinants within the family (data not shown), there-
fore excluding this locus as well. The second family of
Irish background with parent-to-child transmission of
periodic fevers was too small to be informative for link-
age analysis, but no change was identified inTNFRSF1A
when both the coding region and the promoter region
were sequenced.
Moreover, in our mutational survey of 150 patients
with periodic fever and clinical histories suggestive of
TRAPS, 120 had no mutations in exons 2–5. Ninety
patients were further analyzed for mutations in the re-
mainder of TNFRSF1A (exons 1 and 6–10), by a com-
bination of DHPLC and sequencing; no mutation was
identified, except a new polymorphism (i.e., SNP) in in-
tron 8, at position c.218 -9 TrC (fig. 6). This sequence
change was evaluated in 88 control chromosomes
(CEPH and Irish), and allele frequencies were .78 (T)
and .22 (C). In 80 chromosomes from patients, the fre-
quencies were the same—that is, .78 (T) and .22 (C).
Discussion
In the present article, we have reported six novel mu-
tations, in TNFRSF1A, as a cause of the recently de-
scribed dominantly inherited periodic fever syndrome,
TRAPS. These novel mutations confirm our initial report
demonstrating a role for the p55 molecule in the path-
ogenesis of autoinflammatory disease (McDermott et al.
1999). The total number of TNFRSF1A mutations that
have been described thus far is 16, including 4 mutations
(C30S, R92P, C55S, and C70Y) that recently have been
reported elsewhere (Dode´ et al. 2000; Aganna et al.
2001; Jadoul et al. 2001; Simon et al. 2001). In contrast
to our previous study, in which five of six TNFRSF1A
mutations involved cysteine residues, in the present study
five of six novel TRAPS mutations were identified at
noncysteine residues. As a group, the noncysteine mu-
tations are less frequently associated with amyloi-
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dosis—and perhaps are less penetrant—than the cysteine
substitutions.
Our new data are consistent with our previous ob-
servation that dominantly inherited periodic fevers can
be caused by structural changes in the extracellular do-
main of TNFRSF1A, but we now have a broader view
of the mutations that can cause this phenotype. Of the
16 TRAPS mutations described thus far, 15 are mis-
sense, and all 16 are clustered within the first two cys-
teine–rich extracellular subdomains (i.e., CRD1 and
CRD2) of the protein, spanning exons 2–4 of the ge-
nomic sequence (fig. 6). If one of the mechanisms by
which TRAPS mutations cause an autoinflammatory
state is interference with activation-induced receptor
cleavage, then it may well be that more-drastic nonsense
or frameshift mutations, resulting in a truncated or non-
expressed protein, would not have the same phenotype.
Extensive analysis of coding and exon-flanking se-
quences of 90 patients referred for TRAPS did not iden-
tify any disease-causing mutation, either in the trans-
membrane or in intracellular domains of TNFRSF1A.
The nine cysteine substitutions thus far identified all
disrupt conserved extracellular disulfide bonds (fig. 7):
C30R, C30S, C33Y, C33G, and C52F would disrupt
the second or third disulfide bond in the first extracel-
lular subdomain (i.e., CRD1), whereas C55S, C70Y,
C88R, and C88Y would abolish the first or second in-
trachain disulfide bond in the second extracellular sub-
domain (i.e., CRD2). The observation of multiple mu-
tations at residues C30, C33, and C88 suggests a critical
role for these sites that is not immediately apparent from
the p55 crystal structure (Banner et al. 1993; Naismith
et al. 1996).
Among the six noncysteine missense substitutions,
T50M most likely prevents the formation of a highly
conserved intrachain hydrogen bond (fig. 7). Three
other sequence variants—P46L, S86P, and R92P—
involve proline residues that would be predicted to in-
troduce a bend into the protein secondary structure, and
therefore such mutations might have an important effect
on the folding of the extracellular domain. The ligand-
binding domain of the p55 molecule is between amino
acid 77 and amino acid 114 (Banner et al. 1993), and
thus the mutations at residues 86 and 92 may affect
TNF binding. H22Y, P46L, and R92Q fall within the
b turns of loop 3 of CRD1 and CRD2 (fig. 7), and
therefore these replacements may have a significant im-
pact on overall loop structure.
This article is also the first report of a TNFRSF1A
splice mutation associated with periodic fever. We have
provided strong evidence, both from the cDNA se-
quence in patients and from the analysis of minigene
constructs, that the c.19314 GrA mutation results in
the addition of four amino acids to CRD1. This and
other mutations within CRD1 (amino acids 1–54) may
affect the ligand-independent assembly of TNFRSF1A
trimers on the cell membrane (Chan et al. 2000).
We have previously provided evidence that the C52F
mutation is a novel type of dominant negative, in which
“negative” refers not to a failure of signaling but, rather,
to a failure in cytokine-receptor clearance (McDermott
et al. 1999). Receptor cleavage may have a homeostatic
effect both by reducing the number of available
membrane sites for repeated stimulation and by pro-
ducing a pool of potentially antagonistic soluble recep-
tors, and thus a defect in cleavage could lead to a hy-
perinflammatory state. In the present article, we have
extended the finding of impaired activation-induced
shedding to other mutations. However, we were unable
to demonstrate a defect in shedding in vitro for mono-
cytes from patients with R92Q and the splicing muta-
tion, despite the facts that (a) serum p55 levels did not
increase with attacks for R92Q and (b) the splicing mu-
tation was seen only in families with TRAPS symptoms.
These data suggest that additional pathogenetic mech-
anisms may be operative in TRAPS.
The present study also provides important insights
into genotype-phenotype correlations and related issues
of penetrance. This article presents the first compre-
hensive analysis of TNFRSF1A genotypes seen in as-
sociation with systemic amyloidosis, the most serious
and life-threatening complication of TRAPS. Overall,
we found that ∼14% of patients thus far reported with
TRAPS have developed amyloidosis, with the risk
skewed strongly toward individuals with cysteine sub-
stitutions. The prevalence of amyloidosis among pa-
tients with TRAPS is significantly higher than previously
recognized. This is most likely due to the fact that, prior
to the identification of TNFRSF1A as the underlying
gene, it was unclear whether families with periodic fever
and amyloidosis (Gertz et al. 1987; Zaks and Kastner
1997) should be grouped with the index family for FHF,
in which amyloidosis was uncommon. Molecular anal-
ysis has enabled proper diagnosis and the accurate as-
sessment of the true prevalence of this complication.We
also found that, relative to individuals with cysteine
substitutions, individuals with noncysteine mutations
have a tendency toward lower overall penetrance, al-
though it should be emphasized that, even for cysteine
substitutions, penetrance is not 100%. At present, we
have insufficient clinical data to determine whether,
aside from amyloidosis, patients with cysteine substi-
tutions have more-severe disease.
Of the TNFRSF1A substitutions reported here, P46L
and R92Q are likely to have the lowest penetrance for
TRAPS, with each having been found in ∼1% of control
chromosomes. Despite these high frequencies in con-
trols, we believe that both substitutions are either low-
penetrance mutations or functional variants, rather than
benign polymorphisms. As noted above, P46L would
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be predicted to have a significant effect on the loop
structure of p55 molecules, and the one patient with
this substitution whomwe have seen has symptoms very
typical of TRAPS, with a favorable response to anti-
TNF therapy. Moreover, we were able to demonstrate
a defect in activation-induced TNFRSF1A shedding in
monocytes from a patient with P46L. In the case of
R92Q, the clinical picture is somewhat more hetero-
geneous, but the frequency of this substitution in our
cohort with periodic fever was significantly higher than
that in the control population. Although we did not
observe a defect in R92Q TNFRSF1A shedding in vitro,
soluble p55 serum levels in vivo did not increase with
attacks.
On the basis of the hypothesis that R92Q might have
a broader influence on susceptibility to inflammation, we
have examined the frequency of this substitution in a
cohort of 135 patients with early arthritis; we found 7
patients to be positive ( , Fisher exact test), andPp .06
a larger study is in progress. It is possible that the phe-
notypic manifestations of R92Q depend on other linked
or unlinked modifying genes and/or on modifying envi-
ronmental factors (Dipple and McCabe 2000). These re-
sults are particularly intriguing in light of the recently
reported possible susceptibility locus for rheumatoid ar-
thritis, in the TNFRSF1A region of chromosome 12 (Ja-
waheer et al. 2001).
Haplotype analysis of TRAPS chromosomes bearing
R92Q revealed a common intragenic haplotype (G-140
bp-C) associated with this substitution. Since this hap-
lotype comprises only intragenic markers (and does not
extend to flanking microsatellites) and is seen in a num-
ber of different populations, the data suggest a very
ancient common founder. In light of the current theories
of the genetics of complex diseases (Lander 1996; Risch
and Merikangas 1996; Collins et al. 1997), it will be
interesting to determine whether R92Q carriers with
non-TRAPS early arthritis also carry this haplotype. It
is also noteworthy that we did not identify a common
founder haplotype associated with T50M, a mutation
detected in several families of Scottish or Irish descent;
our data suggest instead that T50M is a recurrent mu-
tation arising at a CpG hotspot.
The diversity of T50M carrier chromosomes in the
Scottish/Irish families is but a part of the rather unex-
pected genetic heterogeneity of TRAPS seen in these
populations. Although TRAPS has been seen in several
ethnic groups, a disproportionately large percentage of
families are of Irish or Scottish descent. Altogether, we
have observed 10 of 16 currently known mutations in
families of Irish and/or Scottish ancestry. Although as-
certainment bias remains a possibility that is difficult to
exclude, it is also possible that there is a high frequency
of permissive alleles at one or more interacting loci in
the Irish and Scottish populations, thereby increasing
the penetrance of TNFRSF1A mutations. A similar hy-
pothesis has been proposed to explain the high fre-
quency of limb-girdle type 2A muscular dystrophy on
Reunion Island (the “Reunion Paradox”), as well as
Hurler syndrome and metachromatic leukodystrophy in
the lower Galilee in Israel, in the absence of high-fre-
quency founder mutations (Beckmann 1996).
The last 5 years have witnessed striking advances in
our understanding of the molecular pathogenesis of the
hereditary periodic fevers (Centola et al. 1998; Drenth
and van der Meer 2000). The genes underlying FMF
(French FMF Consortium 1997; International FMF
Consortium 1997), HIDS (Drenth et al. 1999; Houten
et al. 1999), and TRAPS have all been identified, and
susceptibility loci for MWS and FCU have been mapped
to chromosome 1q44 (Cuisset et al. 1999; Hoffman et
al. 2000; McDermott et al. 2000). Data presented in
the present article suggest that yet other loci play a role
in the pathogenesis of periodic fever and inflammation
in man. Whether these loci encode new members of the
pyrin, TNF, or mevalonate pathways or encode proteins
in yet other pathways remains to be established. As is
the case for the p55 TNF receptor, it is likely that these
other genes will eventually be found to play an impor-
tant role in a number of human inflammatory diseases.
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